Clinical Characteristics and Risk Factors for Severe Immune-Related Liver Injury Following Nivolumab and Ipilimumab Combination Therapy - Yuichi Yamazaki; Satoru Kakizaki; Yuki Tamura; Yumeo Tateyama; Tatsuma Murakami; Takuya Adachi; Hiroki Tojima; Toshio Uraoka (Antibodies, 2026)